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Abstract
Objectives: The objectives were to investigate into the relationship between lipid profile including Apolipoprotein-
A1 (Apo-A1) and Apolipoprotein-B (Apo-B) and smokers and to relate them with smoking pack years.
Materials and Methods: A total of 274 active male smokers without any other illnesses and age matched male
healthy control subjects (78) with similar socio-cultural background were assessed for clinical details, dietary habits,
physical activities, smoking and alcohol consumption. Standard methods were adopted to check the lipid levels.
The data were analyzed statistically.
Results: Their ages ranged from 40 to 59 years, systolic BP from 110 to 130 mmHg, and diastolic BP from 76 to
88 mmHg. All of them had similar pattern of diet (vegetarianism with occasional meat). None was on any
medication influences lipid level. Their physical activity was moderate. Number of pack years varied from 10 to
14 (mild), 15 to 19 (moderate) and 20 and above (heavy) among 69, 90 and 115 cases, whose mean ages were 43,
44 and 49 respectively. The mean (+SD) values in mg/dl of total cholesterol (TC), Triglyceride (TGL), Apo-B, low
density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and Apo-A1 in mg/dl among mild/
moderate/ heavy smokers and control subjects were 198 (30.6)/ 224 (27.2)/ 240 (24.3) and 160 (20.4); 164(42.6)/ 199
(39.5)/ 223(41.7) and 124 (31.6); 119 (24.9)/ 121 (27)/ 127 (28.3) and 116 (21.4); 94 (19.7)/ 104 (21.8)/ 120 (20.5) and
82 (17.6); 42 (5.9)/ 39 (3.1)/ 35(4.4) and 48 (5.3); and 120 (17)/ 119 (21)/ 115 (25) and 126 (19), respectively. In
smokers, there was a rise in TC, TGL, LDL, Apo-B and fall in HDL and Apo-A; these changes were significant
(P < 0.05).
Conclusion: Number of pack years was directly proportional to abnormal lipid profile. It is also concluded that
changes in Apo-A1 and Apo-B were more significant when compared to HDL and LDL cholesterol among smokers.
In the view of double risk for smokers (smoking and altered lipid profile) efforts may be made to introduce
smoking cessation program.
Introduction
Smoking is an escalating health problem especially in
developing countries such as India. Cigarette smoking is
a known risk factor for peripheral, coronary and cerebral
atherosclerotic vascular diseases. Cigarette smoking
leads to the uptake of many hazardous compounds and
their metabolites extracted from burning tobacco. These
substances may be electrophilic and react with biological
molecules, and give rise to oxidative stress through the
formation of reactive species or the initiation of lipid
peroxidation chain reactions in the membranes[1].
Plasma lipoprotein abnormalities are major risk factor
for the occurrence of atherosclerotic vascular disease
[2]. The prevalence of smoking in India varies from
about 15% to over 50% among men [3]. However, smok-
ing is less common among women with prevalence of
4% or less [4]. Cigarette smoking has been found to
alter the lipoprotein levels [5].
Previously published reports suggest their oxidatively
modified low density lipoprotein (LDL) is taken up by
macrophages to form foam cells in culture and aggra-
vate the process of atherosclerosis[6]. Also, the effects of
elevated lipid levels and changes in lipoprotein among
cigarette smokers were demonstrated earlier [7], [8-10].
The effects of cigarette smoking on serum apolipopro-
tein A1 (Apo A1) and apolipoprotein B (Apo B) in smo-
kers free from other risk factors of atherosclerotic
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vascular disease and dose response relationship were
studied. The correlation of Apo A1 with high density
lipoprotein cholesterol (HDL) and Apo B with LDL as
coronary risk factors was also examined along with the
effects of smoking on HDL/Apo A1 and LDL/Apo B.
However, studies on the interaction between smoking
and apolipoproteins are scarce. Hence, objectives of the
present study were: (i) to investigate into the lipid pro-
file including Apo-A1 and Apo-B among smokers, and




Middle aged healthy males smoking cigarettes over 10
pack years and hailing from Chennai, capital of Tamil
Nadu State of Southern India attending Master health
checkup program (MHCP) formed the subjects of the
study. Another group of non-smoking age matched
male candidates attending MHCP were included as con-
trol subjects. The work was carried out after an approval
from Institutional ethical committee and informed con-
sent from each participant according to Helsinki
Declaration Guidelines.
Master health checkup program (MHCP)
State Government of Tamil Nadu has introduced
MHCP in Government Medical College hospital and
district head quarters hospitals wherein any interested
or referred persons can ask for health check-up. Sub-
jects are instructed to come in fasting for 12 hours.
During checkup, qualified physician takes complete
health history including health complaints, past, family
and social histories, and physician does general and phy-
sical examination of body systems. Then, individuals are
subjected to laboratory evaluation such as complete
blood count, blood sugar, lipid profile, renal and liver
function, and urine analysis including chest X-ray, ultra
sonogram of abdomen and electrocardiogram for a
nominal fee. If the individual is found to have any ill-
ness, he/she will be referred to respective specialty for
management. Counseling and guidance will be provided
to those who require life style modification.
Inclusion and exclusion criteria
Since smoking is extremely rare among women in this
area due to cultural reasons, women were not included.
Individuals if found to have any associated co-morbid
illness or taking regular medication including vitamin/
mineral supplements/herbal/native medicines were
excluded. Clinical history was elicited to rule out any
acute injury or infectious episode and/or anti-microbial
therapy over the last six weeks. Patients with family his-
tory of lipid disorders were not included.
Data collection
The socio-demographic and clinical data were collected.
Dietary history and physical activity were elicited as per
Indian Council of Medical Research.
Categorization of smokers
Smoking history was elicited in detail and smoking pack
year was then calculated by using formula, {(Number of
cigarettes smoked per day × Number of years smoked)/
20}. In our study, smokers were classified into mild,
moderate and heavy based on the number of pack years
as 10 to 14, 15 to 19, and 20 and above, respectively.
Laboratory aspects
Blood was drawn from the subjects after 12 hours fast-
ing with staple food for two days. Enzymatic method
was used to estimate total cholesterol (TC) and trigly-
cerides (TGL) using commercial kits. HDL cholesterol
was determined by precipitation of phosphotungstic acid
MgCl [11] and LDL cholesterol was then calculated. By
kinetic nephelometry, Apo-A1 and Apo-B were mea-
sured using specific antibodies.
Statistical analysis
The data were tabulated and analyzed. Differences
between mean values were evaluated by student ‘t’ test.
The statistical significance was assessed by using chi-
square test [12].
Results
There were 274 smokers and 78 controls. Their ages ran-
ged from 40 to 59 years. Their systolic blood pressure and
diastolic blood pressure ranged from 110 to 130 and 76 to
88 mmHg, respectively. Most of them were vegetarians
with occasional meat (varied from 3 to 5 times per month)
and rice was their staple food. The subject groups con-
sumed coffee or tea from 2 to 3 times per day. All subject
groups had moderate physical activity of at least 30 min-
utes per day. Overall, there was no difference noticed
among smokers and non-smokers with reference to diet,
physical activity and life style except smoking. Among
smokers the number of pack years varied from 10 to 14,
15 to 19, and 20 and above among 69, 90 and 115 cases,
whose median ages were 43, 44 and 49 respectively. The
mean values of TC, TGL, LDL, HDL, Apo-B and Apo-A1
for smokers and non-smokers (control subjects) are
depicted in Table 1. Among the smokers TC, LDL, TGL
and Apo-B were elevated significantly than control (P <
0.05). HDL and Apo-A1 were not statistically reduced in
mild smokers. Among moderate smokers, HDL was not
significantly reduced (odds ratio (OR) = 1.81, 95% confi-
dence interval (CI) = 0.82-4.02, P > 0.05), however Apo-
A1 was significantly reduced (OR = 2.72, 95% CI = 1.45-
5.10, P < 0.05). In heavy smokers Apo-A1 association (OR
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= 3.33, 95% CI = 1.82-6.10, P < 0.05) was stronger than
HDL (OR = 4.30, 95% CI = 1.73-10.67, P < 0.05). Similarly
LDL and Apo-B were significantly increased among all
groups of smokers (P < 0.05 to 0.00). Concordant increase
of Apo-B with LDL and concordant decrease of Apo-A1
and HDL were noticed among smokers (P < 0.05). The
abnormalities of lipid profile were more significant when
smoking pack year increased. The statistical significance of
lipid profile among smokers is illustrated in Table 2.
Discussion
Previous studies have demonstrated a rise in TC, TGL,
LDL and Apo-B, and a fall in HDL and Apo-A in smo-
kers; and this association is dose dependant [9,10,13]
[14,15]. It has been suggested that smoking, even of short
duration and moderate consumption of cigarettes, is
associated with adverse lipoprotein profiles [16]. Apolipo-
proteins are known to determine the structural stabilities
and metabolic directions of lipoproteins. Of the apolipo-
proteins, Apo-B has identified in VLDL and LDL and
thus appears to be a measure of the total number of
atherogenic particles [17]. Hence, Apo-B is a more accu-
rate measure than LDL with regard to predicting the
CAD. Though LDL and Apo-B were significantly elevated
among all three categories of smoker, Apo-B elevation
was much stronger than LDL. In moderate smokers, only
Apo-A1 was significantly decreased without significant
reduction in HDL level. Apo-A1 association was stronger
than HDL in heavy smokers. Hence, we conclude that
changes in Apo-A1 and Apo-B were significant when
compared to HDL and LDL cholesterol among smokers.
Thus, it is clear that alteration in apolipoproteins occurs
earlier than its corresponding cholesterol, which concurs
with previous observation [18]. Such similar observation
in lipid profile, such as rise in TC, TGL and LDL and fall
in HDL were noted among passive smokers [8,19].
Smoking is associated with coronary artery disease
(CAD) and other vascular disorders, cancer, chronic
obstructive pulmonary disease (COPD) etc., Several
mechanisms were proposed to explain the deleterious
effect of tobacco. For the occurrence of cardiovascular
disease among smokers alteration in plasma lipid profile
was implicated. In this context, the mechanisms for the
altered lipid profile among smokers were recalled [5].
(i) Nicotine stimulates the release of adrenaline from
the adrenal cortex leading to increased serum concen-
tration of free fatty acids (FFA)which further stimulates
hepatic synthesis and secretion of cholesterol [20] as
well as hepatic secretion of very low density lipoprotein
(VLDL) and hence increased TGL [21].
(ii) Smoking decreases estrogen levels and further
leads to decreased HDL cholesterol concentration
[22,23]. Also, HDL concentration was inversely related
to VLDL concentration in serum.
(iii) Smoking increases insulin resistance and thus,
causes hyperinsulinemia. LDL, VLDL and TGL are ele-
vated in hyperinsulinemic conditions due to decreased
activity of lipoprotein lipase [23].
Inconsistent observations were noticed for smoking
mediated LDL change. Some suggested that the effect of
Table 1 Lipid Profile among Smokers and Control subjects:
Lipid (in
mg/dl)
Control, N = 78,
Mean ± SD
Mild (Pack years 10-14) N = 69,
Mean ± SD
Moderate (Pack years 15-19) N = 90,
Mean ± SD
Heavy (Pack Years≥20) N = 115,
Mean ± SD
TC 160 ± 20.4 198 ± 30.6# 224 ± 27.2# 240 ± 24.3#
TGL 124 ± 31.6 164 ± 42.6* 199 ± 39.5# 223 ± 41.7#
LDL-C 82 ± 17.6 94 ± 19.7# 104 ± 21.8# 120 ± 20.5#
HDL-C 48 ± 5.3 42 ± 5.9 39 ± 3.1 35 ± 4.4*
Apo-B 116 ± 21.4 119 ± 24.9# 121 ± 27# 127 ± 28.3#
Apo-A1 126 ± 19 120 ± 17 119 ± 21* 115 ± 25#
# P < 0.001; *P < 0.05; TC = total cholesterol, TGL = triglyceride, LDL-C = low density lipoprotein cholesterol, HDL-C = high density lipoprotein cholesterol,
Apo-B = Apolipoprotein B, Apo-A1 = Apolipoprotein A1, SD = standard deviation, N = number.
Table 2 Odds Ratio (95% Confidence Interval) for Lipid Profile among Smokers:
Lipid (in mg/dl) Mild (Pack years 10-14) Moderate (Pack years 15-19) Heavy (Pack years ≥ 20)
TC (≥ 200) 6.26 (3.04-12.90)# 10.25 (4.94-21.29)# 14.82 (7.10-30.92)#
TGL (≥ 150) 3.13 (1.46-6.70)* 3.91 (1.87-8.13)# 5.67 (2.70-11.87)#
LDL-C (≥ 130) 3.99 (1.20-7.97)# 6.07 (3.06-12.01)# 13.01 (6.19-27.33)#
HDL-C (≤ 40) 1.64 (0.71-3.82) 1.81 (0.82-4.02) 4.30 (1.73-10.67)*
Apo-B (> 110) 6.64 (3.17-13.90)# 9.17 (4.44-18.95)# 17.74 (8.08-38.85)#
Apo-A1(< 110) 1.19 (0.63-2.28) 2.72 (1.45-5.10)* 3.33 (1.82-6.10)#
# P < 0.001; *P < 0.05; TC = total cholesterol, TGL = triglyceride, LDL-C = low density lipoprotein cholesterol, HDL-C = high density lipoprotein cholesterol,
Apo-B = Apolipoprotein B, Apo-A1 = Apolipoprotein A1.
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smoking on LDL is mediated through reduction in lipo-
protein lipase [24,25] which was contradicted by Mori-
guchi and Eliasson et al., that no difference in
lipoprotein lipase activity observed between smokers
and non-smokers [26,27]. Plasma lipase is an important
regulator of plasma lipoprotein concentration. TGL rich
lipoprotein is hydrolyzed by the catalyst lipoprotein
lipase and thus, enables clearance of TGL from blood.
Among smokers, hepatic lipase has been activated [26],
which converts VLDL to LDL[28]. In an experimental
study, it has been shown that smoking leads to inhibi-
tion of lecithin-cholesterol acyl transferase [29]. Nicotine
also exerts hyperlipidemic effects by increasing the
synthesis of TGL rich lipoprotein[30]. It is also interest-
ing to note that smoking induces oxidative stress result-
ing in glutathione peroxidase [GSH-Px] activity where it
increases glutathione reductase (GR) activity in erythro-
cytes. Also, human serum paraoxygenase (PON1) is a
polymorph enzyme which has been shown to play an
important role in lipid metabolism. PON1 significantly
decreases lipid peroxidase generation during LDL oxida-
tion in the presence HDL modification by lipid peroxi-
dase [31,32]. Smoking impairs PON1 activity and
thereby compromises anti-oxidant defense mechanism
[33].
Smokers had significantly higher level of Apo-B
[34,35] and higher level of Apo-B is believed to be
related to the risk of premature CAD [36]. Though the
smokers are considered for the present study did not
show any symptomatic evidence of CAD, increased
levels of Apo-B in them may be a warning sign long
before the onset of symptoms of CAD. In smokers, low
level of Apo-A1 has been associated with significant
atherosclerotic changes in patients undergoing coronary
angiography [37]. Moreover, the ratio of Apo-B to Apo-
A was significantly higher in smokers regardless of sex
[38]. As further evidence in support of casual relation
lipid and lipoprotein concentration in ex-smokers were
either the same as those found in non-smokers or were
intermediate between smokers and non-smokers [5]. In
a longitudinal study, it was observed that HDL and
Apo-A1 levels in ex-smokers return towards base line
concentration seen in non-smokers [39]. Because of
reversible phenomenon, occurrence of lipid profile
alteration and its atherosclerotic complications come
down among middle aged smokers after cessation of
cigarette smoking.
Conclusion
Abnormalities in lipid profile are directly correlated with
smoking and duration of smoking pack years in this
study. Since apolipoprotein changes occur earlier than
cholesterol level, it would be advisable to include
apolipoprotein concentration in lipid panel. Further stu-
dies are warranted to establish the role of apolipoprotein
concentration in patients on lipid lowering therapy as a
guide for response to therapy and genomic factors in
apolipoprotein synthesis. Cessation of smoking not only
reverses lipid changes but also vascular diseases, espe-
cially CAD. Passive smokers are prone to get the same
abnormality as demonstrated in literature and our on-
going analysis. Hence, policy makers should amend a
firm law to prohibit smoking in the public places,
thereby decreasing the passive smokers in the commu-
nity. Intense education program about adverse health
events of smoking should be under taken through all
means including audio-visual media to the public and to
students through their curriculum.
Strengths and limitation
Strength of the study was rigid criteria adopted to select
the subjects. Limitation being the study was confined to
males of specific age group belonging to the same geo-
graphical area.
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